Published in Br J Clin Pharmacol on March 01, 1986
The relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarin. Br J Clin Pharmacol (1988) 1.07
Superwarfarin ingestion. CMAJ (1992) 0.81
A case of bromadiolone (superwarfarin) ingestion. CMAJ (1992) 0.80
Ingestion of superwarfarin leading to coagulopathy: a case report and review of the literature. MedGenMed (2006) 0.80
The long-term effects of the rodenticide, brodifacoum, on blood coagulation and vitamin K metabolism in rats. Br J Pharmacol (1991) 0.79
Vitamin K-dependent formation of gamma-carboxyglutamic acid. Annu Rev Biochem (1977) 2.10
Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry (1978) 1.63
A study of the effect of anticoagulants on [3H]vitamin K1 metabolism and prothrombin complex activity in the rabbit. Biochem Pharmacol (1979) 1.46
STUDIES ON THE COUMARIN ANTICOAGULANT DRUGS: THE PHARMACODYNAMICS OF WARFARIN IN MAN. J Clin Invest (1963) 1.37
Metabolism of vitamin K and prothrombin synthesis: anticoagulants and the vitamin K--epoxide cycle. Fed Proc (1978) 1.33
Warfarin and the inhibition of vitamin K activity by an oxide metabolite. Nature (1972) 1.31
Effect of warfarin on the metabolism of phylloquinone (vitamin K1):dose-response relationships in man. Clin Sci Mol Med (1977) 1.30
Plasma disposition of vitamin K1 in relation to anticoagulant poisoning. Br J Clin Pharmacol (1984) 1.26
Changes in phylloquinone epoxidase activity related to prothrombin synthesis and microsomal clotting activity in the rat. Biochem J (1974) 1.20
Evidence against vitamin K deficiency in normal neonates. Thromb Haemost (1980) 1.13
Vitamin K-dependent carboxylase. Stoichiometry of carboxylation and vitamin K 2,3-epoxide formation. J Biol Chem (1981) 1.10
A comparison of vitamin K antagonism by warfarin, difenacoum and brodifacoum in the rabbit. Biochem Pharmacol (1982) 1.10
Difenacoum (Neosorexa) poisoning. Br Med J (Clin Res Ed) (1982) 1.06
A study of the relationship between the pharmacokinetics and the pharmacodynamics of the 4-hydroxycoumarin anticoagulants warfarin, difenacoum and brodifacoum in the rabbit. Br J Pharmacol (1985) 1.04
Mechanism of coumarin action: sensitivity of vitamin K metabolizing enzymes of normal and warfarin-resistant rat liver. Biochemistry (1982) 0.97
Relationship between vitamin K-dependent carboxylation and vitamin K epoxidation. Fed Proc (1978) 0.94
Vitamin K1 metabolism in relation to pharmacodynamic response in anticoagulated patients. Br J Clin Pharmacol (1985) 0.93
Relationship of dithiothreitol-dependent microsomal vitamin K quinone and vitamin K epoxide reductases inhibition of epoxide reduction by vitamin K quinone. Biochim Biophys Acta (1984) 0.93
Vitamin K-dependent carboxylase: purification of the rat liver microsomal enzyme. Arch Biochem Biophys (1980) 0.93
Epoxidation of several vitamins K by rat liver microsomes. Biochem Pharmacol (1979) 0.86
Comparison of the native prothrombin antigen and the prothrombin time for monitoring oral anticoagulant therapy. Blood (1984) 0.84
Review of company postmarketing surveillance studies. BMJ (1992) 6.21
Cimetidine: interaction with oral anticoagulants in man. Lancet (1979) 4.67
Factor VIII gene rearrangements in patients with severe haemophilia A. Lancet (1994) 3.56
Identity of viridans streptococci isolated from cases of infective endocarditis. J Med Microbiol (1993) 3.36
Measurement of urinary 6-beta-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin. Eur J Clin Pharmacol (1979) 3.32
Adverse drug reactions. BMJ (1998) 3.25
Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol (1994) 3.19
A highly conserved enhancer in the Dlx5/Dlx6 intergenic region is the site of cross-regulatory interactions between Dlx genes in the embryonic forebrain. J Neurosci (2000) 2.98
Hepatitis C antibody and chronic liver disease in haemophilia. Lancet (1990) 2.44
Cerebral intravascular coagulation in diabetic ketoacidosis. Lancet (1974) 2.35
Acute encephalopathy coincident with seroconversion for anti-HTLV-III. Lancet (1985) 2.26
Clinical implications of enzyme induction and enzyme inhibition. Clin Pharmacokinet (1981) 2.25
Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost (1998) 2.20
Essential thrombocythaemia and peripheral gangrene. Br Med J (1974) 2.18
The pharmacokinetics of combination therapy with nelfinavir plus nevirapine. AIDS (1998) 2.16
Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability. Thromb Haemost (1999) 2.15
Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J Thromb Haemost (2005) 2.13
4-Aminoquinolines--past, present, and future: a chemical perspective. Pharmacol Ther (1998) 2.00
An investigation of the pharmacokinetics of ethynylestradiol in women using radioimmunoassay. Contraception (1979) 1.97
Pharmacokinetics of halofantrine in man: effects of food and dose size. Br J Clin Pharmacol (1989) 1.97
Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. J Steroid Biochem Mol Biol (1997) 1.94
A direct radioimmunoassay for 6 beta-hydroxycortisol in human urine. J Steroid Biochem (1978) 1.90
Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J (2006) 1.87
Pharmacokinetics of primaquine in man: identification of the carboxylic acid derivative as a major plasma metabolite. Br J Clin Pharmacol (1984) 1.82
May mothers given warfarin breast-feed their infants? Br Med J (1977) 1.80
Rifampicin and vitamin D metabolism. Clin Pharmacol Ther (1980) 1.78
The natural history of chronic hepatitis C in haemophiliacs. Br J Haematol (1996) 1.76
Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost (1998) 1.71
Inter-subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man. Br J Clin Pharmacol (1989) 1.71
Demonstration of viraemia patterns in haemophiliacs treated with hepatitis-C-virus-contaminated factor VIII concentrates. Lancet (1990) 1.69
Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease. Lancet (1980) 1.68
Thromboplastin related differences in the determination of international normalised ratio: a cause for concern? Steering Committee of the UK National External Quality Assessment Scheme in Blood Coagulation. Thromb Haemost (1994) 1.67
Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS (1997) 1.65
Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol (1990) 1.64
Clinical pharmacokinetics of oral contraceptive steroids. Clin Pharmacokinet (1983) 1.64
The metabolism of 17 alpha-ethinyloestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites. Br J Clin Pharmacol (1987) 1.63
Differential detection of transmissible gastroenteritis virus and porcine epidemic diarrhea virus by duplex RT-PCR. J Vet Diagn Invest (2001) 1.59
Thrombocytosis, circulating platelet aggregates, and neurological dysfunction. Br Med J (1979) 1.59
Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood (1995) 1.59
Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics. Br J Clin Pharmacol (1988) 1.56
The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study. Br J Clin Pharmacol (1991) 1.54
Percutaneous liver biopsy and chronic liver disease in haemophiliacs. Lancet (1978) 1.53
Phylogenetic analysis of swine influenza viruses recently isolated in Korea. Virus Genes (2008) 1.52
Effect of isoniazid on vitamin D metabolism and hepatic monooxygenase activity. Clin Pharmacol Ther (1981) 1.52
Assessment of the drug metabolism capacity of the liver. Br J Clin Pharmacol (1982) 1.51
Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration. Lancet (1994) 1.49
Differentiation of a Vero cell adapted porcine epidemic diarrhea virus from Korean field strains by restriction fragment length polymorphism analysis of ORF 3. Vaccine (2003) 1.47
Drug disposition and drug hypersensitivity. Biochem Pharmacol (1987) 1.46
A study of the effect of anticoagulants on [3H]vitamin K1 metabolism and prothrombin complex activity in the rabbit. Biochem Pharmacol (1979) 1.46
Isolation and phylogenetic analysis of H1N1 swine influenza virus isolated in Korea. Virus Res (2006) 1.45
Lack of effect of ranitidine on warfarin action. Br J Clin Pharmacol (1981) 1.45
Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochem J (1992) 1.44
Trial of combination of guanethidine and oxprenolol in hypertension. Br Med J (1976) 1.44
Familial thrombophilia and lifetime risk of venous thrombosis. J Thromb Haemost (2004) 1.44
Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci (2001) 1.43
The effect of various drugs on the glucuronidation of zidovudine (azidothymidine; AZT) by human liver microsomes. Br J Clin Pharmacol (1991) 1.42
The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. AIDS (1996) 1.41
Increased resistance to acetaminophen hepatotoxicity in mice lacking glutathione S-transferase Pi. Proc Natl Acad Sci U S A (2000) 1.40
The interaction of antibiotics with synthetic steroids in the rat [proceedings]. Br J Pharmacol (1978) 1.40
Interindividual variation and drug interactions with hormonal steroid contraceptives. Drugs (1981) 1.36
Hyposplenism in inflammatory bowel disease. Gut (1978) 1.36
Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmacol (2003) 1.35
4-Hydroxyhexenal is a potent inducer of the mitochondrial permeability transition. J Biol Chem (1996) 1.35
Interindividual differences in the response to oral anticoagulants. Drugs (1977) 1.34
The disposition of amodiaquine in Zambians and Nigerians with malaria. Br J Clin Pharmacol (1990) 1.34
The burden of alcohol misuse on an inner-city general hospital. QJM (2000) 1.31
Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen. J Steroid Biochem Mol Biol (2003) 1.31
Effect of warfarin on the metabolism of phylloquinone (vitamin K1):dose-response relationships in man. Clin Sci Mol Med (1977) 1.30
Determination of primaquine in biological fluids by reversed-phase high-performance liquid chromatography. J Chromatogr (1984) 1.30
An in vitro study of the microsomal metabolism and cellular toxicity of phenytoin, sorbinil and mianserin. Br J Clin Pharmacol (1988) 1.29
High prevalence of a mutation in the factor V gene within the U.K. population: relationship to activated protein C resistance and familial thrombosis. Br J Haematol (1994) 1.29
Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size. Br J Clin Pharmacol (1985) 1.27
Cellular hyperviscosity as a cause of neurological symptoms in leukaemia. Br Med J (1978) 1.27
Application of scanning electron microscopy in assessing the prevalence of some Setaria species in Korean cattle. Korean J Parasitol (1994) 1.27
Urinary excretion of 6 beta-hydroxycortisol and the time course measurement of enzyme induction in man. Eur J Clin Pharmacol (1989) 1.27
The effect of low-dose phenobarbitone on three indices of hepatic microsomal enzyme induction. Br J Clin Pharmacol (1986) 1.26
Assessment of urinary 6 beta-hydroxycortisol as an in vivo index of mixed-function oxygenase activity. Br J Clin Pharmacol (1981) 1.26
Plasma disposition of vitamin K1 in relation to anticoagulant poisoning. Br J Clin Pharmacol (1984) 1.26
Inhibition of prostacyclin and platelet thromboxane A2 after low-dose aspirin. N Engl J Med (1981) 1.22
The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma. Scand J Clin Lab Invest (1985) 1.22
In vitro activities of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte CFUs. Antimicrob Agents Chemother (1995) 1.21
The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism. Br J Clin Pharmacol (1990) 1.21
Cimetidine potentiates the anticoagulant effect of warfarin by inhibition of drug metabolism. Biochem Pharmacol (1980) 1.21
Progressive liver disease in haemophilia: an understated problem? Lancet (1985) 1.19
Prediction of metabolic drug interactions involving beta-adrenoceptor blocking drugs. Br J Clin Pharmacol (1984) 1.19
Vesicular stomatitis virus infection induces a nuclear DNA-binding factor specific for the interferon-stimulated response element. J Virol (1995) 1.19
A randomized controlled trial of recombinant interferon-alpha in chronic hepatitis C in hemophiliacs. Blood (1991) 1.19
Variability in the metabolism of proguanil to the active metabolite cycloguanil in healthy Kenyan adults. Trans R Soc Trop Med Hyg (1991) 1.19
Effects of cimetidine on carbamazepine auto- and hetero-induction in man. Br J Clin Pharmacol (1984) 1.19
Intravascular coagulation and E. coli septicaemia. J Clin Pathol (1973) 1.18